7. INTANGIBLE ASSETS
|9 Months Ended|
Sep. 30, 2018
|7. INTANGIBLE ASSETS||
Intangible assets at September 30, 2018 and December 31, 2017 consist of the following:
All of the Company’s intangible assets were acquired in the Biotest Transaction. Amortization expense related to these intangible assets for the three and nine months ended September 30, 2018 was $0.2 million and $0.6 million, respectively. Amortization expense for the three and nine months ended September 30, 2017 was $0.3 million. Estimated aggregate future aggregate amortization expense for the next five years is expected to be as follows:
The entire disclosure for all or part of the information related to intangible assets.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef